New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the placebo-controlled Part B remains on track for top-line data in the third quarter 2023.
Enrollment completed in Phase 2b/3 randomized controlled trial of izokibep in Psoriatic Arthritis; top-line data now accelerated to first quarter 2024 from mid-2024.
Strong cash position of $823.0 million, including gross proceeds from recent IPO of $621.0 million, supports multiple late-stage clinical programs through key milestones across all three clinical programs.
Company to host conference call and webcast at 4:30 p.m. ET Monday
ACELYRIN will host a conference call and webcast today, August 14, 2023, at 4:30 p.m. ET to review its second quarter 2023 financial results. A live webcast of the conference call can be accessed in the “Investors & Media” section of ACELYRIN’s website at www.acelyrin.com. A recording of the webcast will be available approximately two hours after the event, and will be archived on the Company’s website for approximately 30 days.
https://finance.yahoo.com/news/acelyrin-inc-reports-second-quarter-200500086.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.